Explanipedia

Toward an all-in-one recombinant adeno-associated virus vector for functionally ablating the prion gene using CRISPR-Cas technology Open

Claire Verkuyl, Ari Belotserkovsky, Thomas Zerbes, Declan Williams, M. Krishnan , et al. · 2025

Any strategy that can selectively and persistently lower the brain levels of the cellular prion protein (PrP C ) is expected to extend survival in prion diseases. Recent advances in the virus-mediated delivery of gene therapies prompted us…

Cardiomyocyte-specific RXFP1 overexpression protects against pressure overload-induced cardiac dysfunction independently of relaxin Open

J. P. Wingert, Erik Meinhardt, Nuttarak Sasipong, M. Pott, Ch. Lederer , et al. · 2024

S100A1: a promising therapeutic target for heart failure Open

Dorothea Noll, Dorothea Kehr, Patrick Most, Julia Ritterhoff · 2024

S100A1’s single cysteine is an indispensable redox-switch for the protection against diastolic calcium leakage in cardiomyocytes Open

Andreas Seitz, Martin Busch, Jasmin Kroemer, Andrea Schneider, Stéphanie Simon , et al. · 2023

The EF-hand calcium (Ca 2+ ) sensor protein S100A1 combines inotropic with antiarrhythmic potency in cardiomyocytes (CM). Oxidative posttranslational modification (ox-PTM) of S100A1’s conserved, single cysteine residue (C85) via reactive n…

105 Burning Heart - An Animal Model of Chronic Heart Failure Following Severe Burn Injury Open

Gabriel Hundeshagen, Viktoria Mertin, Martin Busch, Philipp Thiele, Felix A. Trogisch , et al. · 2023

Introduction Our clinical research unveiled chronic heart failure with preserved ejection fraction (HFpEF) as a long-term sequel in survivors of severe pediatric burn injury due to a yet unknown molecular pathomechanism. Applying a standar…

Cardiac-targeted rAAV5-S100A1 gene therapy protects against adverse remodeling and contractile dysfunction in post-ischemic hearts Open

Dorothea Kehr, Janek Salatzki, Birgit Krautz, Karl Varadi, Jennifer Birkenstock , et al. · 2023

Summary Toxicity by recombinant adeno-associated viruses (rAAV) in clinical gene therapy trials (e.g., by rAAV9-mediated fatal liver failure) significantly impairs translation of preclinical rAAV-based cardiac gene therapies employing thes…

S100A1ct: a synthetic peptide derived from human S100A1 protein improves cardiac contractile performance and survival in pre-clinical heart failure models Open

Dorothea Kehr, Julia Ritterhoff, Manuel Glaser, Lukas Jarosch, Rafael Salazar , et al. · 2023

Background The EF-hand Ca 2+ sensor protein S100A1 has been identified as a molecular regulator and enhancer of cardiac performance. S100A1’s ability to recognize and modulate the activity of targets such as SERCA2a and RyR2 in cardiomyocy…

SUMO interacting motif (SIM) of S100A1 is critical for S100A1 post-translational protein stability Open

Zegeye Hailu Jebessa, Manuel Glaser, Jemmy Zhao, Andrea Schneider, Ramkumar Seenivasan , et al. · 2023

S100A1 is a small EF-type Ca 2+ sensor protein that belongs to the multigenic S100 protein family. It is abundantly expressed in cardiomyocytes (CMs) and has been described as a key regulator of CM performance due to its unique ability to …

Chronic heart failure as a sequel of severe burn injury: first insight into a novel pathological heart-skin axis Open

Gabriel Hundeshagen, V Mertin, Martin Busch, P Thiele, Felix A. Trogisch , et al. · 2022

Research question Our clinical research unveiled chronic heart failure with preserved ejection fraction (HFpEF) as a long-term sequel in survivors of severe pediatric burn injury due to a yet unknown molecular pathomechanism (1). Applying …

Current understanding of thermo(dys)regulation in severe burn injury and the pathophysiological influence of hypermetabolism, adrenergic stress and hypothalamic regulation—a systematic review Open

Viktoria Mertin, Patrick Most, Martin Busch, S. Trojan, Christian Tapking , et al. · 2022

Background In this systematic review, we summarize the aetiology as well as the current knowledge regarding thermo(dys)regulation and hypothermia after severe burn trauma and aim to present key concepts of pathophysiology and treatment opt…

Trigger-Specific Remodeling of KCa2 Potassium Channels in Models of Atrial Fibrillation Open

Ann‐Kathrin Rahm, Dominik Gramlich, Teresa Wieder, Mara Elena Müller, Axel Schoeffel , et al. · 2021

Reduction of K_Ca2.1-2.3 channel expression might contribute to the action potential prolongation in AF complicated by HF. Subtype-specific K_Ca2 channel remodeling induced by tachypacing, stretch, β-adrenergic stimulat…

Ligand-activated RXFP1 gene therapy ameliorates pressure overload-induced cardiac dysfunction Open

Nuttarak Sasipong, Philipp Schlegel, Julia Wingert, Christoph Lederer, Eric Meinhardt , et al. · 2021

Consensus Transcriptional Landscape of Human End‐Stage Heart Failure Open

Ricardo O. Ramirez Flores, Jan D. Lanzer, Christian H. Holland, Florian Leuschner, Patrick Most , et al. · 2021

Background Transcriptomic studies have contributed to fundamental knowledge of myocardial remodeling in human heart failure (HF). However, the key HF genes reported are often inconsistent between studies, and systematic efforts to integrat…

Development of an AAV9-RNAi-mediated silencing strategy to abrogate TRPM4 expression in the adult heart Open

Rebekka Medert, Andreas Jungmann, Staffan Hildebrand, Martin Busch, Dirk Grimm , et al. · 2021

The cation channel transient receptor potential melastatin 4 (TRPM4) is a calcium-activated non-selective cation channel and acts in cardiomyocytes as a negative modulator of the L-type Ca 2+ influx. Global deletion of TRPM4 in the mouse l…

A Consensus Transcriptional Landscape of Human End-Stage Heart Failure Open

Ricardo O. Ramirez Flores, Jan D. Lanzer, Christian H. Holland, Florian Leuschner, Patrick Most , et al. · 2020

2. Abstract Aims Transcriptomic studies have contributed to fundamental knowledge of myocardial remodeling in human heart failure (HF). However, the agreement on key regulated genes in HF is limited and systematic efforts to integrate evid…

The Reference of the Transcriptional Landscape of Human End-Stage Heart Failure Open

Ricardo O. Ramirez Flores, Jan D. Lanzer, Christian H. Holland, Florian Leuschner, Patrick Most , et al. · 2020

Data from: "The Reference of the Transcriptional Landscape of Human End-Stage Heart Failure" Source code at: https://github.com/saezlab/HF_meta-analysis Aims: Transcriptomic studies have contributed to fundamental knowledge of myocardial r…

From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases Open

Ulf Landmesser, Wolfgang Poller, Sotirios Tsimikas, Patrick Most, Francesco Paneni , et al. · 2020

Nucleic acid-based therapeutics are currently developed at large scale for prevention and management of cardiovascular diseases (CVDs), since: (i) genetic studies have highlighted novel therapeutic targets suggested to be causal for CVD; (…

Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy Open

Ibrahim El‐Battrawy, Zhihan Zhao, Huan Lan, Xin Li, Gökhan Yücel , et al. · 2018

Background: Limb-Girdle muscular dystrophies (LGMD) are a heritable group of genetically determined disorders with a primary involvement of the pelvic or shoulder girdle musculature with partially cardiac manifestation, such as dilated car…

Pathogenic Role of the Damage-Associated Molecular Patterns S100A8 and S100A9 in Coxsackievirus B3–Induced Myocarditis Open

Irene Müller, Thomas J. Vogl, Kathleen Pappritz, Kapka Miteva, Konstantinos Savvatis , et al. · 2017

Background: The alarmins S100A8 and S100A9 are damage-associated molecular patterns, which play a pivotal role in cardiovascular diseases, inflammation, and viral infections. We aimed to investigate their role in Coxsackievirus B3 (CVB3)–i…

S100A6 Regulates Endothelial Cell Cycle Progression by Attenuating Antiproliferative Signal Transducers and Activators of Transcription 1 Signaling Open

Carolin Lerchenmüller, Julian Heißenberg, Federico Damilano, Vassilios J. Bezzeridis, Isabel Krämer , et al. · 2016

Objective— S100A6, a member of the S100 protein family, has been described as relevant for cell cycle entry and progression in endothelial cells. The molecular mechanism conferring S100A6’s proliferative actions, however, remained elusive.…

Erratum: Myoscape controls cardiac calcium cycling and contractility via regulation of L-type calcium channel surface expression Open

Matthias Eden, Benjamin Meder, Mirko Völkers, Montatip Poomvanicha, Katrin Domes , et al. · 2016

Myoscape controls cardiac calcium cycling and contractility via regulation of L-type calcium channel surface expression Open

Matthias Eden, Benjamin Meder, Mirko Völkers, Montatip Poomvanicha, Katrin Domes , et al. · 2016

S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction Open

Julia Ritterhoff, Mirko Völkers, Andreas Seitz, Kristin Spaich, Erhe Gao , et al. · 2015

Cardiomyocytes, Endothelial Cells and Cardiac Fibroblasts: S100A1’s Triple Action in Cardiovascular Pathophysiology Open

David Rohde, Martin Busch, Anne Volkert, Julia Ritterhoff, Hugo A. Katus , et al. · 2015

Over the past decade, basic and translational research delivered comprehensive evidence for the relevance of the Ca(2+)-binding protein S100A1 in cardiovascular diseases. Aberrant expression levels of S100A1 surfaced as molecular key defec…

Prediction of functional recovery by cardiac magnetic resonance feature tracking imaging in first time ST-elevation myocardial infarction. Comparison to infarct size and transmurality by late gadolinium enhancement Open

Sorin Giuşcă, Birgit Krautz, Yannick Sander, Lukas Rust, Christian Galuschky , et al. · 2015

FRET-Based RyR-Selective Detection Reveals No Significant Competition between CaM and S100A1 Binding to RyRs Open

Robyn T. Rebbeck, Florentin R. Nitu, David Rohde, Patrick Most, Donald M. Bers , et al. · 2015

Translationale Therapeutik von Kardiomyopathien und Kanalerkrankungen; präklinische Evaluation und Entwicklung neuer Targets : Standortprojekt: HD/MA 2.4 B-HIC$dAbschlussbericht HD/MA 2.4 B-HIC : Laufzeit des Projektes: 01.01.2011-31.03.2015 Open

Patrick Most, Angiologie Und Pneumologie Klinik Für Kardiologie · 2015

Großtierplattform : HD/MA I.4-SCI : Abschlussbericht HD/MA I.4-SCI : Laufzeit des Projektes: 01.01.2011-31.03.2015 Open

Patrick Most, Angiologie Und Pneumologie Klinik Für Kardiologie · 2015

Patrick Most YOU? Author Swipe